Celltrion's Jimpentra Sees Threefold Increase in U.S. Prescriptions
Shipments Increase 3.5-Fold, Confirming Rising Demand
Coverage Secured for Over 90% of Insurance Market, Laying the Foundation for Further Expansion
Celltrion's subcutaneous (SC) formulation of infliximab, 'Jimpentra', is showing growth in the U.S. market, with both prescriptions and shipments increasing simultaneously.
On March 18, Celltrion announced that the number of Jimpentra prescriptions in the U.S. in January of this year increased by approximately three times (213%) compared to the same period last year, reaching a record monthly high. This figure exceeds the entire prescription volume for the first quarter of last year.
Shipments in February also increased by about 3.5 times compared to the same period last year. The company explained that, given the nature of biopharmaceuticals, the expansion of shipments reflects an actual increase in prescription demand.
The scope of insurance coverage has also expanded. Celltrion stated that, through contracts with major U.S. pharmacy benefit managers (PBMs), it has secured coverage for more than 90% of the total insurance market. In January of this year, Evernorth Health Services, a subsidiary of the Cigna Group, listed Jimpentra as a preferred medication in its formulary. The company explained that prescription growth continued through what it calls a '3P strategy' targeting healthcare professionals, insurers, and patients.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion official said, "The increase in prescriptions is based on actual demand growth," and added, "We will continue to expand prescriptions in the U.S. market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.